AIXCRYPTO HOLDINGS INC

AIXCNASDAQ

🏆 #3619 by market capEarnings Nov 17US Equity

$0.80▲ $0.01 (+1.04%)

🌙 After hours$0.80▲ 0.08%Regular close · extended-hours price shown

1h—

24h▲ 1.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$16M

Small Cap

📈Revenue Growth (YoY)

+26.7%

High Growth

📊Gross Margin

23.1%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

2.6x

Cheap

Otter Score

Weak

No chart data available for AIXC.

Trading Snapshot

Day Range: $0.79 – $0.80
52-Week Range: $0.62 – $8.81
Volume: $3.07B
Avg Volume: $3.46B
Shares Outstanding: 20.2M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 2.6x
EPS (TTM): $-7.35
Dividend Yield: —

Why Investors Own AIXC

✓High-growth profile — revenue up -8.5% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▼ −4.1% YoY

Gross Margin (TTM)

50.7%▲ +1.7% YoY

Operating Income (TTM)

$2M▼ −4.1% YoY

Free Cash Flow (TTM)

$880,155▼ −4.1% YoY

About AIXCRYPTO HOLDINGS INC

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

🦦